Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
tuberculosis/protease
Link salvestatakse lõikelauale
15 tulemused
Second-line Switch to Dolutegravir Study
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Background and Purpose of Research:
Current Kenya National Antiretroviral(ARV) Guidelines recommend that after failing an NNRTI-based first line regimen, patients should move to a ritonavir-boosted protease inhibitor (PI/r) + 2 nucleoside reverse transcript inhibitors second line regimen. Several
Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A significant barrier to the use of better tolerated antiretrovirals in many low-to-middle income countries (LMIC), where tuberculosis (TB) is endemic, is a lack of evidence to support their use in patients with TB. Access to optimal protease inhibitor (PI)-based regimens for patients with and
HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
1. Introduction
Hepatitis C infection is a major cause of chronic liver disease and death throughout the world1. Approximately 3% of the world's population is infected with hepatitis C virus (HCV)2.
HCV is transmitted by blood and in the UK occurs primarily through injecting drug use. Chronically
Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Antiretroviral therapy (ART) in pregnancy is able to effectively reduce mother-to-child transmission (MTCT) of HIV. If untreated, the risk of transmission is around 25% (greater with high viral loads) but ART administered optimally during pregnancy may reduce this risk to 1-2%. In order to
Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Biomarker Levels During Indwelling Pleural cAtheter Sample Testing
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
An alternative and emerging treatment for malignant pleural effusions is the placement of a chronic indwelling pleural catheter.
Tunneled pleural catheters (TPC) are ideal for treatment of malignant pleural effusion (MPE) associated with a trapped or non-expandable lung which will not have
Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Drug interactions complicate concurrent treatment of HIV and Mycobacterium tuberculosis co-infection. Drug therapy for HIV and tuberculosis each consists of combined regimens with three or four drugs. Tuberculosis (TB) is the most significant co-infection of HIV patients in resource-limited
EARNEST Rifabutin Pharmacokinetics (PK) Substudy
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
- Summary Background and aims
The standard anti-tuberculosis drug, rifampicin, has major drug-drug interactions with the cornerstone of second-line therapy in resource-limited settings, lopinavir/ritonavir (Aluvia tablets). Concomitant administration of rifampicin and lopinavir/ritonavir reduces
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively high doses of ritonavir appear necessary to overcome this interaction, but it is unclear whether the co-treatment regimen of RIF-based TB treatment and double-dose PI-based
Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND AND RATIONALE The HIV and TB epidemics disproportionately affect sub-Saharan Africa, and have had a catastrophic impact in the region. The synergy between these pathogens has resulted in dramatic increases in TB incidence, with 58% of cases of adult TB in 2005 in South Africa being
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Some attempts have been made to evaluate the pharmacokinetics of lopinavir using ritonavir as booster by some researchers with dosages of 400/100 and 533/133 mg (the last dosage would be achieved with an additional capsule of lopinavir/ritonavir) but the results were disappointing because AUC was
TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This is a Phase I, open-label, randomized, 3-way crossover trial in 18 healthy volunteers to investigate the potential drug-drug interaction between rifampin and TMC435350. TMC435350 is a protease inhibitor in development for treatment of chronic HCV infection. The goal is to assess the PK and
Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The study consist in a open label randomized clinical trial comparing efavirenz 600mg QID versus efavirenz 800mg QID in patients with tuberculosis (treated with regimens including rifampicin) and AIDS diagnosis. The total duration of the study is 6 months for each patient. All eligible patient will
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TB is common in resource-limited countries, and people infected with HIV are especially at risk for TB infection. The antituberculous drug RIF lowers plasma concentrations of PIs by increasing the activity of enzymes responsible for PI breakdown. RIF has been shown to reduce PI effectiveness, a
Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Currently, rifabutin is the only rifamycin that can be administered with indinavir. ACTG 365 is the first formal study of the pharmacokinetics of this dosing combination regimen in HIV seropositive patients. It is hypothesized that staggered administration of rifabutin and indinavir might minimize
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
